Clinical Trial Update: Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating three-times-per-week oral dosing of vadadustat for anemia in dialysis-dependent CKD has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Dialysis-dependent Chronic Kidney Disease

Drugs mentioned

• Vadadustat (vadadustat)

Snippet

Sponsor: Akebia Therapeutics | Conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease | Phase 3 | Status: WITHDRAWN